Key clinical point: Secukinumab showed early and clinically meaningful improvements in patient-reported outcomes (PRO) in adults with psoriatic arthritis (PsA).
Major finding: At week 16, patients in all secukinumab treatment groups vs. placebo showed significant improvement in all PRO ( P ≤ .0001) except for the 36-item Short-Form Health Survey mental component summary. Patients receiving 300 mg secukinumab showed significant and clinically meaningful improvements as early as week 1 ( P < .05).
Study details: Findings are from the phase 3 FUTURE 5 trial including 996 adults with active PsA who were randomly assigned to 300 mg secukinumab, 150 mg secukinumab (with/without loading dose), or placebo.
Disclosures: This study was funded by Novartis Pharma. Some of the authors declared receiving research grants or consulting and speaker’s bureau fees from various sources including Novartis. Four authors declared being past/current employees or shareholders of Novartis.
Source: Strand V et al. Lancet Rheumatol. 2022 (Feb 1). Doi: 10.1016/S2665-9913(21)00354-4.